Organon (OGN) Amortizatization of Intangibles (2020 - 2026)
Organon (OGN) recorded quarterly Amortizatization of Intangibles of $47.0 million in Q1 2026, down 6.0% quarter-over-quarter from $50.0 million in Q4 2025, and down 6.0% on a YoY basis from $50.0 million in Q1 2025.
Organon (OGN) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Organon's Amortizatization of Intangibles history runs 7 years deep, the most recent figure standing at $47.0 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 6.0% year-over-year to $47.0 million; the TTM figure through Mar 2026 stood at $202.0 million (up 24.69% YoY), while the FY2025 annual figure was $205.0 million, up 41.38% from the prior year.
- Amortizatization of Intangibles was $47.0 million for Q1 2026 at Organon, down from $50.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $53.0 million in Q2 2025 to a low of $28.0 million in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $37.0 million across 5 years, with a median of $33.0 million in 2024.
- The sharpest annual moves came in 2022 and 2025: Amortizatization of Intangibles decreased 17.65% in 2022, then surged 55.88% in 2025.
- A 5-year view of Amortizatization of Intangibles shows it stood at $28.0 million in 2022, then changed by 0.0% to $28.0 million in 2023, then jumped by 53.57% to $43.0 million in 2024, then grew by 16.28% to $50.0 million in 2025, then slipped by 6.0% to $47.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $47.0 million (Q1 2026), $50.0 million (Q4 2025), and $52.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,162,528.78 Bn | 93,162,523.82 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,017.87 Bn | 1,012.58 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 575.51 Bn | 553.46 Bn | 15.96 Bn | - |
| 4 | AbbVie | 400.43 Bn | 391.08 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 294.19 Bn | 288.54 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 182.41 Bn | 170.37 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 150.97 Bn | 143.24 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 145.75 Bn | 132.97 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 113.35 Bn | 102.90 Bn | 8.07 Bn | - |
| 10 | Organon | 3.48 Bn | 2.37 Bn | 783.00 Mn | 47.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 47.00 Mn |
| Mar 31, 2026 | 47.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Dec 31, 2025 | 50.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Sep 30, 2025 | 52.00 Mn |
| Jun 30, 2025 | 53.00 Mn |
| Jun 30, 2025 | 53.00 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Mar 31, 2025 | 50.00 Mn |
| Dec 31, 2024 | 43.00 Mn |
| Dec 31, 2024 | 43.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Sep 30, 2024 | 35.00 Mn |
| Jun 30, 2024 | 34.00 Mn |
| Jun 30, 2024 | 34.00 Mn |
| Mar 31, 2024 | 33.00 Mn |
| Mar 31, 2024 | 33.00 Mn |
| Dec 31, 2023 | 28.00 Mn |
| Dec 31, 2023 | 28.00 Mn |